As previously reported, Oppenheimer analyst Christopher Marai upgraded Sarepta to Outperform from Perform and reinstated a $60 price target on the stock after saying he has uncovered several findings supporting eteplirsen's accelerated approval case, including identifying other "highly negative" panel votes that have previously been overruled by the FDA, particularly for unmet need. Marai, who believes Sarepta offers a compelling risk/reward into the upcoming PDUFA date of May 26 for eteplirsen, also thinks the acquisition comps of competitors Santaris and Prosensa place a floor on Sarepta's valuation.